Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy
Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy
复制标题
DOI：
10.1016/j.ejca.2005.08.026
复制
发表时间：
2005-12-01
影响因子：
8.4
通讯作者：
Picci, P
中科院分区：
文献类型：
--
作者：
Bacci, G;Longhi, A;Picci, P
1972 年至 1999 年间，大约 1148 名四肢非转移性骨肉瘤患者在一个机构接受了 4 种不同的辅助化疗方案和 7 种不同的新辅助化疗方案的治疗。保肢率从20%提高到71%。 5 年无事件生存率 (EFS) 和总生存率 (OS) 分别为 57% 和 66%。 10年EFS和OS分别为52%和57%，结果与血清碱性磷酸酶水平显着相关；化疗类型（辅助化疗与新辅助化疗）；以及对术前治疗的组织学反应。积极的化疗和手术可以治愈大约60%的四肢骨肉瘤患者。然而，由于自治疗开始后 5 年或更长时间内也可能出现局部或全身复发、心肌病和继发恶性肿瘤，因此建议进行长期随访。 (c) 2005 Elsevier Ltd. 保留所有权利。
Around 1148 patients with non-metastatic osteosarcoma of the extremity were treated in a single institution between 1972 and 1999 with 4 different protocol of adjuvant and 7 different protocols of neoadjuvant chemotherapy. The rate of limb salvage increased from 20% to 71%. The 5-year event-free survival (EFS) and overall survival (OS) were 57% and 66%, respectively. The 10-year EFS and OS were 52% and 57%, respectively, and the results significantly correlated with serum alkaline phosphatase levels; the type of chemotherapy (adjuvant vs neoadjuvant); and with histologic response to pre-operative treatment. Aggressive chemotherapy and surgery could cure about the 60% of patients with osteosarcoma of the extremity. However, since local or systemic relapses, myocardiopathies and a second malignancy are possible even 5 or more years since the beginning of treatment, a long-term follow-up is recommended. (c) 2005 Elsevier Ltd. All rights reserved.